A Systematic Review of Chemotherapeutic Regimens Used in Pancreatic Cancer

• Published in: Curēus (Palo Alto, CA) CA), 2023-10, Vol.15 (10), p.e46630-e46630
• Main Authors: Awais, Nimra, Satnarine, Travis, Ahmed, Areeg, Haq, Ayesha, Patel, Deepkumar, Hernandez, Grethel N, Seffah, Kofi D, Zaman, Mustafa Abrar, Khan, Safeera
• Format: Article
• Language: English
• Subjects: Cancer therapies; Chemotherapy; Dermatology; Drug therapy; Immunotherapy; Internal Medicine; Libraries; Oncology; Pancreatic cancer; Quality of life; Radiation therapy; Surgery; Surgical outcomes; Systematic review; Tumors
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.46630

Pancreatic cancer is a malignant tumor with one of the worst prognosis. Its incidence has been on the rise in recent years. First-line and second-line treatments as well as adjuvant therapies have been employed in clinical trials for pancreatic cancer along with traditional chemotherapy and radiotherapy that has been enhanced. The prognosis of pancreatic ductal adenocarcinoma (PDAC) is still quite bad despite recent improvements in diagnostic and treatment methods. Since most patients are not candidates for treatment with a curative purpose, effective palliative care is crucial. For this systematic review, between December 25, 2022, and January 5, 2023, we searched PubMed, Medline, Cochrane, and Science Direct and discovered 225 relevant articles. The appropriateness of the literature abstracts for the pooled analysis was evaluated using different combinations of keywords such as pancreatic cancer, first- and second-line chemotherapy, palliative chemotherapy, gemcitabine and nab-paclitaxel (GnP), FOLFIRINOX (FFX), and fluorouracil. Eight research studies with a total of 15,236 people, including systematic reviews, meta-analyses, and randomized controlled trials (RCTs), were included. The only treatment of choice for patients without metastatic disease who have clinical staging that suggests resectable or borderline resectable pancreatic cancer (BRPC) should be resection. This research examined how first- and second-line chemotherapeutic regimens (using different drug combinations) affected patients with locally advanced pancreatic cancer (LAPC) or BRPC and how they responded in terms of overall survival (OS), tumor resectability, and progression-free interval. The review concludes by highlighting the results of these therapies. Notably, a growing body of research indicates that the two most popular first-line medication combinations GnP and FFX have similar results in RCTs and in real-world populations. Results of second-line therapy after first-line regime failure are still dismal, and there is still a great deal of doubt regarding the best course of action. More RCTs and real-world evidence studies that address current and innovative regimens, as well as the best order in which to administer them, are required, with a greater emphasis on targeted therapy with fewer side effects.